From: Potential therapeutic approach of intravenous immunoglobulin against COVID-19
Studies suggesting against the use of IVIG | Type of Study | Number of Cases | Dosage of IVIG | Measurement of treatment success | Other therapies used in the course of disease | Comorbidities | Additional Explanations |
---|---|---|---|---|---|---|---|
Liu et al. [51] | Retrospective | 109 | – | Did not lower mortality rate in hospital stay (42 days) | Antivirals, glucocorticoid | Varied (diabetes, cerebrovascular disease, chronic kidney disease, etc.) | No significant effect of antivirus, glucocorticoid, or immunoglobulin treatment on survival was observed in patients with ARDS |
Pei et al. [52] | Systematic review and meta-analysis | 1142 | Varied | Varied | Antivirals, antibiotics, glucocorticoid | Varied | intravenous immunoglobulin had a nonsignificant effect on mortality |